MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application regarding MN-001 (tipelukast) and its metabolite MN-002, aimed at treating scleroderma/systemic sclerosis.
This patent is expected to expire no earlier than June 2035 and covers various administration forms and dosing frequencies. The CMO believes this patent could enhance the value of MN-001. The compound is in clinical development for several conditions, including NASH and IPF, with positive results in previous trials.
MediciNova, Inc. has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a patent covering MN-001 (tipelukast) and MN-002, aimed at treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. This patent is expected to expire no earlier than July 2034. The allowed claims encompass uses for reducing triglycerides, cholesterol, and LDL levels, supporting various dosage forms. Clinical data indicates MN-001 shows significant triglyceride reduction in patients with hypertriglyceridemia and diabetes. A new Phase 2 trial is ongoing to further assess its effectiveness.
MediciNova has completed a Phase I clinical trial of MN-166 (ibudilast), showing a favorable safety and tolerability profile in healthy volunteers. The intravenous (IV) formulation was well tolerated, with no concerning adverse events reported. This formulation targets inflammatory disorders such as acute respiratory distress syndrome (ARDS) and offers a treatment option for hospitalized patients unable to take oral medication. The company is seeking FDA guidance for future development and potential approval of this formulation.
MediciNova, a clinical-stage biopharmaceutical company, announced positive results from a subgroup analysis of its Phase 2 clinical trial for MN-001 (tipelukast) at the International Diabetes Federation World Diabetes Congress 2022. The analysis revealed that participants with Type 2 diabetes mellitus (T2DM) experienced a greater reduction in serum triglyceride levels compared to those without T2DM (50.8% vs 17.8%). Additionally, significant increases in HDL levels were noted in the T2DM group. MediciNova is pursuing further trials to evaluate the efficacy of MN-001 in patients with T2DM and hypertriglyceridemia.
MediciNova announced positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) for treating alcohol use disorder (AUD), published in The American Journal of Drug and Alcohol Abuse. The analysis indicated that participants with elevated C-reactive protein (CRP) levels showed significant improvements in drinking behaviors and neural activation when treated with MN-166. This suggests potential clinical utility for individuals with AUD and high inflammation, highlighting the need for effective treatments.
MediciNova, Inc., a biopharmaceutical company listed on NASDAQ (MNOV), is set to hold one-on-one virtual meetings with investors during the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. CEO Yuichi Iwaki and VP Geoffrey O'Brien will represent the company. Investors can schedule meetings with Lytham Partners.
The company is developing therapies for various diseases, primarily through its lead assets: MN-166 and MN-001, with clinical trials underway for conditions like ALS and idiopathic pulmonary fibrosis.
MediciNova, Inc. announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) for treating glioblastoma. This patent is set to expire no earlier than February 2039 and encompasses treatment methods for various glioblastoma types when combined with other drugs like temozolomide. The company is conducting ongoing trials at the Dana-Farber Cancer Institute. Additionally, MN-166 has been granted orphan-drug designation for glioblastoma, highlighting its potential in this aggressive cancer sector.
MediciNova, Inc. has announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering MN-001 (tipelukast) and its metabolite MN-002. This patent will focus on treating hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. The patent is expected to expire no earlier than July 2034. In its Phase 2 trial, MN-001 noticeably reduced serum triglycerides. The compound has multiple mechanisms of action and is currently undergoing further clinical trials, including for type 2 diabetes patients with hypertriglyceridemia.
MediciNova (NASDAQ: MNOV) announced collaboration with the University Health Network for the RECLAIM clinical trial aimed at treating Long COVID with MN-166 (ibudilast). This grant-funded trial, led by Dr. Angela M. Cheung, awaits protocol finalization and regulatory review. Long COVID affects 10-30% of COVID-19 survivors, causing persistent symptoms like fatigue and brain fog. MN-166 is in late-stage development for various diseases, including ALS and multiple sclerosis, highlighting MediciNova's commitment to addressing significant health challenges.
MediciNova, a biopharmaceutical company (NASDAQ:MNOV), announced that its abstract, titled “Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes and NAFLD Patients,” has been selected for presentation at the International Diabetes Federation (IDF) 2022 Congress on December 5-8, 2022. The presentation will be led by Chief Medical Officer, Kazuko Matsuda, MD. This study highlights MN-001's effectiveness in improving lipid profiles in NAFLD patients with Type 2 diabetes, showcasing significant results from a Phase 2 trial.